ReviewJournal of clinical medicine2019
Cushing's Disease.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06701838 (Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Osilodrostat Therapy and 11C-methionine PET to IMprove Corticotroph Pituitary Adenoma Detection and Localisation in Patients With Cushing's Disease
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Predictors of long-term remission following trans-sphenoidal surgery in cushing's disease: a systematic review and meta-analysis based on different remission criteria.Neurosurgical review · 2026Pooled it
- Prospective Multicenter Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Adrenocorticotropin-secreting pituitary macroadenomas: expanding the clinical spectrum.JCEM case reports · 2026Article
- Outcomes of endoscopic transsphenoidal pituitary surgery in patients with Cushing's disease: A retrospective review.Surgical neurology international · 2026Article
- New Trends in Treating Cushing's Disease.TouchREVIEWS in endocrinology · 2024Article
- Granulation Patterns of Functional Corticotroph Tumors Correlate with Tumor Size, Proliferative Activity, T2 Intensity-to-White Matter Ratio, and Postsurgical Early Biochemical Remission.Endocrine pathology · 2024Article
- Retrospective analysis of the outcomes of endoscopic transsphenoidal surgery for Cushing's disease.Surgical neurology international · 2024Article
- Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.Translational research : the journal of laboratory and clinical medicine · 2023Article
- The Significance of Dual-Energy X-ray Absorptiometry (DXA) Examination in Cushing's Syndrome-A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Association of IGF-1 Level with Low Bone Mass in Young Patients with Cushing's Disease.International journal of endocrinology · 2023Article
- Predicting delayed remission in Cushing's disease using radiomics models: a multi-center study.Frontiers in oncology · 2023Article
- Apoptosis Evaluation in Circulating CD34+-Enriched Hematopoietic Stem and Progenitor Cells in Patients with Abnormally Increased Production of Endogenous Glucocorticoids in Course of Cushing's Syndrome.International journal of molecular sciences · 2022Article
- Approach to the Patient: Diagnosis of Cushing Syndrome.The Journal of clinical endocrinology and metabolism · 2022Article
- Article
- Article
- Pituicytoma Associated with Suspected Cushing's Disease: Two Case Reports and a Literature Review.Journal of clinical medicine · 2022Article
- Article
- Pharmacological management of severe Cushing's syndrome: the role of etomidate.Therapeutic advances in endocrinology and metabolism · 2022Review
- Assessment of Vitamin D Metabolism in Patients with Cushing's Disease in Response to 150,000 IU Cholecalciferol Treatment.Nutrients · 2021Article
- Rapidly progressive ACTH-dependent Cushing's disease masquerading as ectopic ACTH-producing Cushing's syndrome: illustrative case.Journal of neurosurgery. Case lessons · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with Cushing's disease (CD), prompt diagnosis and treatment are essential for favorable long-term outcomes, although this remains a challenging task. The differential diagnosis of CD is still difficult in some patients, even with an organized stepwise diagnostic approach. Moreover, despite the use of high-resolution magnetic resonance imaging (MRI) combined with advanced fine sequences, some tumors remain invisible. Surgery, using various surgical approaches for safe maximum tumor removal, still remains the first-line treatment for most patients with CD. Persistent or recurrent CD after unsuccessful surgery requires further treatment, including repeat surgery, medical therapy, radiotherapy, or sometimes, bilateral adrenalectomy. These treatments have their own advantages and disadvantages. However, the most important thing is that this complex disease should be managed by a multidisciplinary team with collaborating experts. In addition, a personalized and individual-based approach is paramount to achieve high success rates while minimizing the occurrence of adverse events and improving the patients' quality of life. Finally, the recent new insights into the pathophysiology of CD at the molecular level are highly anticipated to lead to the introduction of more accurate diagnostic tests and efficacious therapies for this devastating disease in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.